[{"address1": "1200 Brickell Avenue", "address2": "Suite 1950 #1183", "city": "Miami", "state": "FL", "zip": "32183", "country": "United States", "phone": "786-432-9792", "website": "https://mirapharmaceuticals.com", "industry": "Drug Manufacturers - General", "industryKey": "drug-manufacturers-general", "industryDisp": "Drug Manufacturers - General", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Erez  Aminov", "age": 45, "title": "CEO & Chairman", "yearBorn": 1978, "fiscalYear": 2023, "totalPay": 337047, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Michelle  Yanez M.B.A.", "age": 51, "title": "CFO, Secretary & Treasurer", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 338774, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Itzchak  Angel Ph.D.", "title": "Chief Scientific Advisor", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.13, "open": 1.17, "dayLow": 1.12, "dayHigh": 1.3, "regularMarketPreviousClose": 1.13, "regularMarketOpen": 1.17, "regularMarketDayLow": 1.12, "regularMarketDayHigh": 1.3, "forwardPE": -2.632653, "volume": 5531355, "regularMarketVolume": 5531355, "averageVolume": 1502300, "averageVolume10days": 1080400, "averageDailyVolume10Day": 1080400, "marketCap": 20983268, "fiftyTwoWeekLow": 0.51, "fiftyTwoWeekHigh": 6.4, "fiftyDayAverage": 1.369, "twoHundredDayAverage": 1.16646, "currency": "USD", "enterpriseValue": 16243561, "floatShares": 9961430, "sharesOutstanding": 16266100, "sharesShort": 342576, "sharesShortPriorMonth": 255602, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.0211, "heldPercentInsiders": 0.2721, "heldPercentInstitutions": 0.050329998, "shortRatio": 0.7, "shortPercentOfFloat": 0.027999999, "impliedSharesOutstanding": 16266100, "bookValue": 0.15, "priceToBook": 8.599999, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -12784287, "trailingEps": -0.86, "forwardEps": -0.49, "52WeekChange": -0.3737864, "SandP52WeekChange": 0.39389753, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "MIRA", "underlyingSymbol": "MIRA", "shortName": "MIRA Pharmaceuticals, Inc.", "longName": "MIRA Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1692019800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "a71f8b50-3996-3ccd-98e2-c993481fee2f", "messageBoardId": "finmb_1793899557", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.29, "targetHighPrice": 17.75, "targetLowPrice": 7.5, "targetMeanPrice": 12.08, "targetMedianPrice": 11.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 2823781, "totalCashPerShare": 0.191, "quickRatio": 3.545, "currentRatio": 3.681, "returnOnAssets": -1.77528, "returnOnEquity": -7.48586, "freeCashflow": -4450804, "operatingCashflow": -4709749, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-28"}]